The OReO Study

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)

Study design & Protocol
Study design
Key Inclusion criteria
Patient population
Recruitment and retention tools

OReO
Olaparib Retreatment in Ovarian Cancer

OReO/GINECO ENGOT-ov38

Trial setting: **non-mucinous EOC (including patients with fallopian tube and/or primary peritoneal cancer)**

Study Design: **Phase IIIb, Randomised, Double-blind, Placebo-controlled**,

Sponsor(s): **AstraZeneca**

Planned No. of patients: **416**

Current accrual: ***First patient in June***

OReO Study: Olaparib Retreatment in Platinum-Sensitive Ovarian Cancer



Stratification factors

- **Prior bevacizumab**
- **<3 vs ≥3 chemo lines**

Rational of prior PARPi exposure time

Median PFS of Study 19 (Olaparib) and NOVA (Niraparib) Patients According to BRCA Status and Treatment Arm, and Selection of Patients in OReO According to Previous Exposure to PARPi				
	BRCAm placebo arm late relapse	**BRCAm Olaparib arm late relapse**	**BRCAwt placebo arm late relapse**	**BRCAwt Olaparib arm late relapse**
	Median PFS (months)			
Study 19	**4.3**	**11.2**	**5.5**	**5.6**
NOVA	**5.5**	**21.0**	**3.9**	**9.3**
Selection in OReO according to previous PARPi exposure **for relapse patients**		**> 12**		**> 6**
Selection in OReO according to previous PARPi exposure for **first line patients**		**> 18**		**> 12**

STUDY DESIGN – BRCA1/2 (+VE) COHORT

- Response: CR or PR to most recent platinum CT (No Bevacizumab)
- Allowed subjects with additional line of chemo (+/- Bev) after PARPi and prior to most recent platinum-based chemotherapy
- Entry based on length of first PARPi exposure

136 patients patients in a 2:1 ratio

BRCA+

- 18mo+ after 1st line CT
- 12 mo+ after 2nd line CT



Hazard ratio of olaparib maintenance versus placebo of **0.61** (corresponding to a median PFS of 12 months in placebo versus 24 months with olaparib)

STUDY DESIGN – BRCA1/2 (-VE) COHORT

- Response: CR or PR to most recent platinum CT (No Bevacizumab)
- Allowed subjects with additional line of chemo (+/- Bev) after PARPi and prior to most recent platinum-based chemotherapy
- Entry based on length of first PARPi exposure

280 patients patients in a 2:1 ratio

BRCA-ve

- 12 mo+ after 1st Line CT
- 6 mo+ after 2nd line+ CT



* an interval after stopping PARPi is allowed

Hazard ratio of olaparib maintenance versus placebo of **0.73** (corresponding to 4.3 month (53.8%) increase in median PFS beyond the 8 months expected for patients on placebo)

STUDY OBJECTIVES

Primary Objective:

- To determine the efficacy of olaparib re-treatment compared to matching placebo by assessment of Progression free survival (PFS).

Secondary Objectives:

- To determine the efficacy of olaparib re-treatment compared to matching placebo by assessment of:
  - Overall survival (OS)
  - the use of subsequent therapies and study treatment discontinuation
  - time to progression (TTP) by Gynecologic Cancer Intergroup (GCIG) criteria
- To determine the Health-related Quality of Life (HRQoL) of olaparib re-treatment compared to matching placebo as measured by the Functional Assessment of Cancer Therapy – Ovarian (FACT-O)

Safety Objective:

- To evaluate the safety and tolerability of olaparib maintenance re-treatment
  - General safety (AEs/SAEs)
  - Advers events of special interest (AESI)
  - Clinical chemistry/haematology parameters (safety Lab data)